To read this content please select one of the options below:

A policy-making strategy to forecast outcomes of drug development in Indonesia

Ria Christine Siagian (Fakultas Kesehatan Masyarakat, Universitas Indonesia and Badan Pengawas Obat dan Makanan, Jakarta, Indonesia)
Anhari Achadi (Fakultas Kesehatan Masyarakat, Universitas Indonesia, Depok, Indonesia)
Hasbullah Thabrany (Fakultas Kesehatan Masyarakat, Universitas Indonesia, Depok, Indonesia)
Dumilah Ayuningtyas (Fakultas Kesehatan Masyarakat, Universitas Indonesia, Depok, Indonesia)
Prastuti Soewondo (Fakultas Kesehatan Masyarakat, Universitas Indonesia, Depok, Indonesia)
Sutanto Priyo Hastono (Fakultas Kesehatan Masyarakat, Universitas Indonesia, Depok, Indonesia)
Purnawan Junadi (Fakultas Kesehatan Masyarakat, Universitas Indonesia, Depok, Indonesia)
Novilia Sjafri Bachtiar (Bio Farma, Bandung, Indonesia)
Tepy Usia (Badan Pengawas Obat dan Makanan, Jakarta, Indonesia)

International Journal of Health Governance

ISSN: 2059-4631

Article publication date: 27 March 2020

Issue publication date: 11 June 2020

255

Abstract

Purpose

The pharmaceutical industry in Indonesia appears hesitant to make the transition from inventor to innovator and instead continues with the process of formulation and packaging. Evidence-based policy has been advocated for Indonesia and, in general, this is more likely to hold. This study aims to establish a model for a policy-making process that is strategically able to predict strategies that would encourage drug development in Indonesia.

Design/methodology/approach

A quantitative approach with the survey method was designed to obtain appropriate data from a population of pharmaceutical industries in Indonesia and relevant government institutions to assess the relationship of various factors capable of triggering domestic drug development, including pharma capability, political feasibility and innovation incentives. The construct was validated using a set of techniques pertaining to the calculation of structural equation modeling.

Findings

The model demonstrates how it matters when applied to the policy-making process. It proves that pharma capability, political feasibility, and innovation incentives correlated to pharma capability are major catalysts in the promotion of drug development. These are largely explained by market opportunity, pull factors, government power, and position. Although all of the elements were moderately to strongly related to the promotion of drug development, this study has revealed the predictive impact on drug development in Indonesia to be only 46%.

Originality/value

This study adds values to policy-makers as it attempts to predict strategies that would encourage a successful policy when being implemented. Encompassing both pharma industries and government institutions, this study captures a real situation and provides an empirical contribution to the concept of the integrated research of drug development in developing countries.

Keywords

Acknowledgements

Disclaimers The views expressed in this work are our own solely based on results of the work and not an official position of the institution or funder.Source of support The work was supported by Badan POM to RCS scholarship. There was no additional external funding received for this study. The funder has no role in study design, data collection and analysis, decision to publish, or the preparation of the manuscript.

Citation

Siagian, R.C., Achadi, A., Thabrany, H., Ayuningtyas, D., Soewondo, P., Hastono, S.P., Junadi, P., Bachtiar, N.S. and Usia, T. (2020), "A policy-making strategy to forecast outcomes of drug development in Indonesia", International Journal of Health Governance, Vol. 25 No. 2, pp. 137-149. https://doi.org/10.1108/IJHG-12-2019-0083

Publisher

:

Emerald Publishing Limited

Copyright © 2020, Emerald Publishing Limited

Related articles